Mallinckrodt (NYSE:MNK) Has Target Of $20 Give by Equity Analysts at B. Riley FBR. “Neutral” Didn’t change.

June 29, 2018 - By Amber Marburger

During Q1 2018 the big money sentiment increased to 0.9. That’s change of 0.19, from 2017Q4’s 0.71. 38 investors sold all, 85 reduced holdings as Mallinckrodt Public Limited Company ratio is positive. 64 rose positions while 47 funds acquired positions. Funds hold 96.44 million shares thus 6.30% more from 2017Q4’s 90.73 million shares.

Ls Invest Advsr Limited Liability Com has 4,911 shs. Community Financial Bank Na has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Services Automobile Association holds 16,406 shs or 0% of its capital. California State Teachers Retirement has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Blackrock has 0.01% invested in Mallinckrodt Public Limited Company (NYSE:MNK). Texas Permanent School Fund stated it has 0.01% in Mallinckrodt Public Limited Company (NYSE:MNK). 513,393 are owned by Neuberger Berman Gru Ltd Llc. Victory Capital Mngmt has invested 0% of its capital in Mallinckrodt Public Limited Company (NYSE:MNK). Ameriprise Financial stated it has 0% of its capital in Mallinckrodt Public Limited Company (NYSE:MNK). Convergence Invest Ltd Liability Com reported 0.07% in Mallinckrodt Public Limited Company (NYSE:MNK). 631,130 were accumulated by Ajo L P. Bessemer Grp Inc owns 41 shs for 0% of their capital. Nj State Employees Deferred Compensation Plan has invested 0.04% in Mallinckrodt Public Limited Company (NYSE:MNK). Point72 Asset Mngmt Ltd Partnership invested in 742,200 shs. Cibc Mkts holds 0% or 19,854 shs.

Mallinckrodt Public Limited Company had 1 sale and 1 insider buy since May 9, 2018. This’s net activity of $4.14 million. On Wednesday, May 9 $4.19 million worth of Mallinckrodt Public Limited Company (NYSE:MNK) was sold by Flynn James E.

Reiterated Mallinckrodt (NYSE:MNK) Rating.

In an analyst report sent to clients and investors by B. Riley FBR’s stock analysts, Mallinckrodt (NYSE:MNK) had it’s stock Rating reaffirmed to “Neutral”. On Thursday morning it has $20 or 7.18 % target price that would indicate a potential upside move.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

A total of 12 analysts rate Mallinckrodt (NYSE:MNK) as follows: 4 “Buy”, 7 “Hold” and 1 “Sell”. Тherefore 33% are bullish. (NYSE:MNK) has 22 ratings reports on Jun 29, 2018 according to StockzIntelligence. The company rating was maintained by Cantor Fitzgerald on Monday, April 2. The stock rating was maintained by Mizuho with “Hold” on Friday, April 20. In Monday, April 23 report Leerink Swann maintained it with “Hold” rating and $1500 target. On Tuesday, February 27 Cantor Fitzgerald maintained Mallinckrodt Public Limited Company (NYSE:MNK) rating. Cantor Fitzgerald has “Buy” rating and $42.0 target. On Tuesday, February 27 Jefferies maintained the shares of MNK in report with “Buy” rating. The company rating was maintained by Mizuho on Friday, March 9. On Tuesday, January 9 the firm has “Hold” rating given by Mizuho. On Thursday, April 26 the firm has “Hold” rating given by Mizuho. On Tuesday, February 27 the stock of Mallinckrodt Public Limited Company (NYSE:MNK) has “Hold” rating given by Mizuho. On Thursday, April 12 the firm has “Hold” rating given by Stifel Nicolaus.

MNK reached $18.66 during the last trading session after $0.52 change.Mallinckrodt Public Limited Company has volume of 1.25 million shares. Since June 29, 2017 MNK has declined 59.76% and is downtrending. MNK underperformed by 72.33% the S&P500.

Mallinckrodt Public Limited Company (NYSE:MNK)’s earnings report is expected on August, 14., as reported by RTT. earnings per share of $1.49 is 19.46 % down from 2017’s $1.85 EPS. MNK’s profit could hit $123.77 million if the current earnings per share of $1.49 is accurate. Wall Street now forecasts 13.74 % EPS growth despite Mallinckrodt Public Limited Company last quarter’s EPS of $1.31.

Mallinckrodt public limited company develops, makes, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions.The firm is worth $1.55 billion. The firm markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.1.02 is the P/E ratio. It offers H.P.

More recent Mallinckrodt Public Limited Company (NYSE:MNK) news were published by Streetinsider.com, Seekingalpha.com and Streetinsider.com. The first one has “Aurobindo Said in Advanced Talks to buy Mallinckrodt’s (MNK) Specialty Generics Business – CNBC-TV18” as a title and was published on June 28, 2018. The next is “Mallinckrodt: The Cheapest Stock In Global Healthcare” on June 08, 2018. And last was published on June 28, 2018, called “Mallinckrodt (MNK) Reports Complete Enrollment Target for Rheumatoid Arthritis Phase 4 Clinical Study for HP Acthar …”.

Mallinckrodt Public Limited Company (NYSE:MNK) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: